Clinical Trial: An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07392255) titled 'An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)' on Jan. 23.

Brief Summary: This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).

Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.

Study Start Date: Dec. 30, 2025

Study Type: INTERVENTIONAL

Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration

Intervention: GENETIC: CTx...